THIS WEEK'S FEATURE
For the first time in a century, administration of epidural needles is being transformed with a smart device developed by closely-held Omeq Medical, which has completed a proof of concept (POC) preclinical study, is currently preparing for FDA submission, and expects to initiate first-in-human trials later this year.
Centurion BioPharma, a newly-created private subsidiary of CytRx (NASDAQ:CYTR) is currently in discussions with a number of pharma companies for a strategic alliance to continue development of its patient-identifying companion diagnostic and Linker-Activated Drug Release (LADR) anti-cancer drug candidates.
Closely-held Intellijoint Surgical plans to improve patients’ lives by providing every orthopaedic surgeon with their surgical 3D solution that provides real-time intraoperative measurements to ensure accurate size selection and positioning of artificial implants during total hip arthroplasty (THA), which involves replacement of the damaged portion of the hip with artificial components.
Closely-held Kardium hopes to receive marketing approval in Europe in the fourth quarter of 2018 and launch its breakthrough Globe mapping and ablation system of cardiac tissue for the treatment of atrial fibrillation (AF), the most common heart rhythm disorder where the atrium quivers instead of beating in regular rhythm.
Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells.